ArticleAbdominal radiology (New York)2026
Scrotal uptake on PSMA PET in prostate cancer: differentiating metastases from benign and physiologic findings using ultrasound correlation.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify imaging and clinical features that aid in distinguishing metastatic lesions from benign or physiologic uptake on PSMA PET, using correlation with scrotal ultrasound.
methodsThis IRB-approved retrospective study included prostate cancer (PCa) patients who underwent PSMA PET-CT or PET-MRI between July 2021 and May 2025, with a scrotal ultrasound performed within 100 days of the scan. PSMA-avid lesions were assessed for uptake intensity (mild vs. intense), distribution (diffuse vs. focal), laterality (unilateral vs. bilateral), scan indication (initial staging vs. restaging), and SUVmax. Ultrasound findings were reviewed, and metastasis was confirmed by pathology or clinical consensus by three board-certified radiologists. Multivariable logistic regression using LASSO was performed to identify predictors of testicular or paratesticular metastasis.
resultsOf 114 patients (mean age 70), 24 (21%) demonstrated scrotal PSMA uptake. Focal intense uptake was seen in 6 patients (all unilateral), and mild focal uptake in 17 (13 bilateral, 4 unilateral). One patient showed mild diffuse bilateral uptake; no cases had intense diffuse uptake. Metastasis was confirmed in 5 patients, all of whom showed focal, unilateral, intense uptake. Among the 17 with mild focal uptake, 16 (94%) had no ultrasound abnormalities, consistent with physiologic epididymal uptake. Of 12 patients with ultrasound findings of epididymitis or orchitis, only 2 showed PSMA uptake (1 intense, 1 mild), while 10 had none. LASSO regression identified uptake intensity, SUVmax, PET indication, and laterality as significant predictors of metastasis. PET indication showed the strongest association with metastasis (coefficient = 4.60), followed by uptake intensity (3.97), SUVmax (1.37), and laterality (0.37), indicating a higher likelihood of metastasis in unilateral, intensely avid lesions, particularly in restaging settings.
conclusionFocal, unilateral, intense PSMA uptake, especially during restaging, was strongly associated with testicular or paratesticular metastasis. In contrast, mild or bilateral uptake without ultrasound abnormalities was typically physiologic. Combined assessment using PSMA PET and scrotal ultrasound improves diagnostic accuracy in evaluating scrotal findings in PCa patients.
Indexed as
Identifiers
41801384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.